GBAP1

GBAP1 — Glucosylceramidase Beta Pseudogene 1

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4ea;">GBAP1 — Glucosylceramidase Beta Pseudogene 1</th></tr>
<tr><td><b>Full Name</b></td><td>Glucosylceramidase Beta Pseudogene 1</td></tr>
<tr><td><b>Symbol</b></td><td>GBAP1</td></tr>
<tr><td><b>Chromosome</b></td><td>1q21</td></tr>
<tr><td><b>Gene ID</b></td><td>26235</td></tr>
<tr><td><b>Ensembl ID</b></td><td>ENSG00000144040</td></tr>
<tr><td><b>UniProt ID</b></td><td>[Q9HCG7](https://www.uniprot.org/uniprot/Q9HCG7)</td></tr>
<tr><td><b>Gene Type</b></td><td>Pseudogene</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">4 edges</a></td>
</tr>
</table>
</div>

Overview

GBAP1 (Glucosylceramidase Beta Pseudogene 1) is a pseudogene located on chromosome 1q21, adjacent to the functional [GBA](/genes/gba) gene. While originally classified as a non-functional pseudogene due to multiple stop codons and frameshift mutations, increasing evidence suggests that GBAP1 may have regulatory functions and play a role in [Parkinson's disease](/diseases/parkinsons-disease) susceptibility[@gba2009]. The [GBA](/entities/gba)/GBAP1 locus represents one of the most significant genetic risk factors for PD identified to date, with variants in this region conferring 2-5 fold increased risk.

Gene Structure and Evolution

GBAP1 — Glucosylceramidase Beta Pseudogene 1

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4ea;">GBAP1 — Glucosylceramidase Beta Pseudogene 1</th></tr>
<tr><td><b>Full Name</b></td><td>Glucosylceramidase Beta Pseudogene 1</td></tr>
<tr><td><b>Symbol</b></td><td>GBAP1</td></tr>
<tr><td><b>Chromosome</b></td><td>1q21</td></tr>
<tr><td><b>Gene ID</b></td><td>26235</td></tr>
<tr><td><b>Ensembl ID</b></td><td>ENSG00000144040</td></tr>
<tr><td><b>UniProt ID</b></td><td>[Q9HCG7](https://www.uniprot.org/uniprot/Q9HCG7)</td></tr>
<tr><td><b>Gene Type</b></td><td>Pseudogene</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">4 edges</a></td>
</tr>
</table>
</div>

Overview

GBAP1 (Glucosylceramidase Beta Pseudogene 1) is a pseudogene located on chromosome 1q21, adjacent to the functional [GBA](/genes/gba) gene. While originally classified as a non-functional pseudogene due to multiple stop codons and frameshift mutations, increasing evidence suggests that GBAP1 may have regulatory functions and play a role in [Parkinson's disease](/diseases/parkinsons-disease) susceptibility[@gba2009]. The [GBA](/entities/gba)/GBAP1 locus represents one of the most significant genetic risk factors for PD identified to date, with variants in this region conferring 2-5 fold increased risk.

Gene Structure and Evolution

GBAP1 shares approximately 96% sequence similarity with [GBA](/genes/gba) and is located in close proximity to it on chromosome 1. The gene arose through gene duplication events during primate evolution and accumulated mutations that impaired its original enzymatic function, resulting in a processed pseudogene with multiple inactivating mutations[@molecular2018].

Genomic Context

• Chromosome: 1q21.3
• Genomic coordinates: chr1:155,234,654-155,245,892 (GRCh38)
• Orientation: Forward strand
• Size: ~11 kb
• Distance from GBA: ~16 kb downstream

Evolutionary History

The GBA family expanded through:

Inactivating Mutations

| Mutation Type | Location | Effect |
|---------------|----------|--------|
| W330X | Exon 5 | Nonsense |
| D409H | Exon 9 | Missense (inactivating) |
| Rec501fs | Exon 11 | Frameshift |
| Multiple splice site | Various | Aberrant splicing |

Expression Patterns

Tissue Distribution

GBAP1 shows expression patterns distinct from GBA:

• Highest expression: Brain tissue (cerebral [cortex](/brain-regions/cortex), cerebellum)
• Moderate expression: Peripheral tissues (liver, spleen, kidney)
• Cell-type specific: [Neurons](/entities/neurons) and glia

Brain Region Expression

| Region | Expression Level | Notes |
|--------|-----------------|-------|
| Substantia nigra | High | Dopaminergic neurons |
| Cortex | High | Pyramidal neurons |
| [Hippocampus](/brain-regions/hippocampus) | Moderate | CA regions, dentate gyrus |
| Cerebellum | High | Purkinje cells |
| White matter | Low | Myelinated fibers |

Differential Expression in PD

GBAP1 expression is altered in [Parkinson's disease](/diseases/parkinsons-disease):

• Increased expression: In PD substantia nigra
• Altered splice patterns: Aberrant transcripts
• Correlation with disease: Severity-linked expression

Functional Implications

Potential Functions

Although classified as a pseudogene, GBAP1 may have several biological functions:

1. Regulatory Role

GBAP1 may regulate the expression of nearby genes:

• Promoter activity: Contains regulatory elements
• Transcription factor binding: Estrogen response elements
• Enhancer function: Long-range gene regulation

2. Competitive Endogenous RNA (ceRNA)

May act as a competing endogenous RNA:

• Shared miRNA binding sites: With GBA and other transcripts
• Sponging effect: Modulates gene expression
• Tissue-specific regulation: Brain-enriched function

3. Lysosomal Function Influence

May affect lysosomal function indirectly:

• Metabolic cross-talk: With functional GBA
• Substrate competition: For trafficking machinery
• Membrane composition: Affects lysosomal lipids

Protein Products

Despite being classified as a pseudogene, GBAP1 may produce:

Role in Disease

Parkinson's Disease

GBAP1 has been implicated in [Parkinson's disease](/diseases/parkinsons-disease) risk through genetic association studies. The GBA/GBAP1 locus represents one of the most significant genetic risk factors for PD identified to date[@gba2009][@gba2020].

Mechanisms of Risk

Key Findings

• GBA/GBAP1 variants increase PD risk 2-5 fold
• Association stronger in certain ethnic populations (Ashkenazi Jewish)
• Earlier onset age in carriers (by 5-10 years)
• Higher prevalence of cognitive impairment
• More rapid disease progression
• Typical phenotype: Tremor-dominant, good levodopa response

Genetic Associations

| Variant | Effect | OR | Population |
|---------|--------|-----|------------|
| L444P (GBA) | Severe | 5.0 | All |
| N370S (GBA) | Moderate | 2.5 | European |
| RecNciI (GBA) | Severe | 4.5 | All |
| GBAP1 promoter | Modest | 1.5 | European |

Gaucher Disease

While GBAP1 itself does not cause [Gaucher disease](/diseases/gaucher-disease), its relationship with [GBA](/genes/gba) is important for understanding the spectrum of glucocerebrosidase-related disorders[@lysosomal2014]:

• Modifier gene: Affects disease severity
• Carrier status: Heterozygous carriers at increased PD risk
• Anticipation effects: Parent-of-origin effects

Other Neurological Disorders

Potential role in:

• Lewy body dementia: Shared pathology with PD
• Multiple system atrophy: α-synucleinopathies
• Progressive supranuclear palsy: Tauopathies
• [Alzheimer's disease](/diseases/alzheimers-disease): Lysosomal dysfunction

Relationship to GBA

The GBAP1-[GBA](/genes/gba) locus is complex and evolutionarily interesting:

Genomic Architecture

| Feature | GBA | GBAP1 |
|---------|-----|-------|
| Chromosome | 1q21.3 | 1q21.3 |
| Function | Functional enzyme | Pseudogene |
| Protein Product | Glucocerebrosidase | None/Low |
| Exons | 11 | 11 (mutated) |
| Disease Association | Gaucher disease, PD | PD risk |

Functional Interaction

The GBA-GBAP1 relationship involves:

Clinical Implications

Understanding this relationship is critical for:

• Genetic counseling: Risk assessment for carriers
• Therapeutic Development: Must consider both genes
• Patient stratification: Genotype-specific approaches

Therapeutic Implications

Understanding GBAP1 function has significant therapeutic relevance[@targeting2018]:

1. Gene Therapy Considerations

• Must account for GBAP1: Regulatory effects on expression
• Vector design: Avoid disrupting GBAP1 regulatory elements
• Promoter selection: Tissue-specific expression patterns

2. Small Molecule Therapy

• GBA activators: May need to account for GBAP1 status
• Chaperone therapy: Patient-specific considerations
• Substrate reduction: Broader metabolic targeting

3. Biomarkers

• GBA/GBAP1 ratio: Potential PD biomarkers
• Expression levels: Disease progression markers
• Genotype-phenotype: Predictive value

4. Combination Approaches

• Dual targeting: Both GBA and downstream pathways
• Lysosomal + cytosolic: Comprehensive approach
• Symptomatic + disease-modifying: Combined benefits

Animal Models

Mouse Models

• Gba knockout mice: Show Gaucher-like phenotypes
• Transgenic GBAP1: Overexpression studies
• Humanized mice: GBA/GBAP1 locus knock-in

Zebrafish Models

• Morpholino knockdown: Developmental studies
• CRISPR mutants: Functional characterization

In Vitro Models

• iPSC-derived neurons: Patient-specific models
• Organoids: 3D brain models
• Cell lines: HEK293, SH-SY5Y

Research Directions

Current Focus

Emerging Areas

• Single-cell analysis: Cell-type specific expression
• Spatial transcriptomics: Tissue-level mapping
• CRISPR screening: Genetic modifiers
• Proteomics: Post-translational modifications

Clinical Trials

Currently, no GBAP1-specific clinical trials. However, GBA-targeted trials may include GBAP1-stratified subjects:

• NCT number: Various Phase 1/2 trials
• Substrate reduction therapy: Eliglustat, Migalastat
• Chaperone therapy: Ambroxol, AT2101

Clinical Perspectives

Diagnosis

• Genetic testing: GBAP1/GBA variants in PD panels
• Enzyme activity: GBA activity measurements
• Biomarkers: Under investigation

Patient Management

• GBA/GBAP1 carriers: More frequent monitoring
• Early intervention: Pre-symptomatic treatment
• Cognitive screening: Neuropsychological assessment

Future Directions

• Personalized medicine: Genotype-specific therapies
• Combination approaches: Multi-target strategies
• Disease modification: Early intervention

Cross-Links

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [GBA Gene](/genes/gba)
• [GBA2 Gene](/genes/gba2)
• [GBA3 Gene](/genes/gba3)
• [GBA Protein](/proteins/gba-protein)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Lysosomal Dysfunction Pathway](/mechanisms/lysosomal-dysfunction)
• [Mitochondrial Dysfunction Pathway](/mechanisms/mitochondrial-dysfunction-pathway)
• [Gaucher Disease](/diseases/gaucher-disease)

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• GBA Gene
• GBA2 Gene
• GBA3 Gene
• [GBA Protein](/proteins/gba-protein)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Lysosomal Dysfunction](/mechanisms/lysosomal-dysfunction)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
• [Gaucher Disease](/diseases/gaucher-disease)

External Links

• [UniProt: Q9HCG7](https://www.uniprot.org/uniprot/Q9HCG7)
• [Ensembl: ENSG00000144040](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000144040)
• [NCBI Gene: 26235](https://www.ncbi.nlm.nih.gov/gene/26235)
• [PDGene: GBA/GBAP1](https://www.pdgene.org/)
• [OMIM: GBA/GBAP1 locus](https://omim.org/)
• [Allen Human Brain Atlas - GBAP1](https://human.brain-map.org/microarray/search/show?search_term=GBAP1)
• [Allen Cell Type Atlas - gbap1](https://celltypes.brain-map.org/)
• [Allen Mouse Brain Atlas - gbap1](https://mouse.brain-map.org/)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving GBAP1 discovered through SciDEX knowledge graph analysis:

Pathway Diagram

The following diagram shows the key molecular relationships involving GBAP1 discovered through SciDEX knowledge graph analysis: